These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9866823)

  • 1. Advances in the understanding of early Huntington's disease using the functional imaging techniques of PET and SPET.
    Andrews TC; Brooks DJ
    Mol Med Today; 1998 Dec; 4(12):532-9. PubMed ID: 9866823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Huntington's disease progression. PET and clinical observations.
    Andrews TC; Weeks RA; Turjanski N; Gunn RN; Watkins LH; Sahakian B; Hodges JR; Rosser AE; Wood NW; Brooks DJ
    Brain; 1999 Dec; 122 ( Pt 12)():2353-63. PubMed ID: 10581228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease.
    Antonini A; Leenders KL; Spiegel R; Meier D; Vontobel P; Weigell-Weber M; Sanchez-Pernaute R; de Yébenez JG; Boesiger P; Weindl A; Maguire RP
    Brain; 1996 Dec; 119 ( Pt 6)():2085-95. PubMed ID: 9010012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study.
    Pavese N; Andrews TC; Brooks DJ; Ho AK; Rosser AE; Barker RA; Robbins TW; Sahakian BJ; Dunnett SB; Piccini P
    Brain; 2003 May; 126(Pt 5):1127-35. PubMed ID: 12690052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical deficits in Huntington disease correlate with reduced striatal uptake on iodine-123 epidepride single-photon emission tomography.
    Leslie WD; Greenberg CR; Abrams DN; Hobson D
    Eur J Nucl Med; 1999 Nov; 26(11):1458-64. PubMed ID: 10552088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cortical atrophic-hypometabolic dissociation in the transition from premanifest to early-stage Huntington's disease.
    Sampedro F; Martínez-Horta S; Perez-Perez J; Horta-Barba A; Lopez-Mora DA; Camacho V; Fernández-León A; Gomez-Anson B; Carrió I; Kulisevsky J
    Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1111-1116. PubMed ID: 30627816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [11C]raclopride-PET studies of the Huntington's disease rate of progression: relevance of the trinucleotide repeat length.
    Antonini A; Leenders KL; Eidelberg D
    Ann Neurol; 1998 Feb; 43(2):253-5. PubMed ID: 9485067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET Imaging in Huntington's Disease.
    Roussakis AA; Piccini P
    J Huntingtons Dis; 2015; 4(4):287-96. PubMed ID: 26683130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease.
    Russell DS; Barret O; Jennings DL; Friedman JH; Tamagnan GD; Thomae D; Alagille D; Morley TJ; Papin C; Papapetropoulos S; Waterhouse RN; Seibyl JP; Marek KL
    JAMA Neurol; 2014 Dec; 71(12):1520-8. PubMed ID: 25322077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study.
    Feigin A; Leenders KL; Moeller JR; Missimer J; Kuenig G; Spetsieris P; Antonini A; Eidelberg D
    J Nucl Med; 2001 Nov; 42(11):1591-5. PubMed ID: 11696626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain imaging and cognitive dysfunctions in Huntington's disease.
    Montoya A; Price BH; Menear M; Lepage M
    J Psychiatry Neurosci; 2006 Jan; 31(1):21-9. PubMed ID: 16496032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional caudate imaging in symptomatic Huntington's disease: positron emission tomography versus single-photon emission computed tomography.
    Martin WR; Hoskinson M; Kremer B; Maguire C; McEwan A
    J Neuroimaging; 1995 Oct; 5(4):227-32. PubMed ID: 7579751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease.
    Ginovart N; Lundin A; Farde L; Halldin C; Bäckman L; Swahn CG; Pauli S; Sedvall G
    Brain; 1997 Mar; 120 ( Pt 3)():503-14. PubMed ID: 9126061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine D1 receptor number--a sensitive PET marker for early brain degeneration in Huntington's disease.
    Sedvall G; Karlsson P; Lundin A; Anvret M; Suhara T; Halldin C; Farde L
    Eur Arch Psychiatry Clin Neurosci; 1994; 243(5):249-55. PubMed ID: 8172940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status of PET imaging in Huntington's disease.
    Pagano G; Niccolini F; Politis M
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1171-82. PubMed ID: 26899245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Striatal hypometabolism in premanifest and manifest Huntington's disease patients.
    López-Mora DA; Camacho V; Pérez-Pérez J; Martínez-Horta S; Fernández A; Sampedro F; Montes A; Lozano-Martínez GA; Gómez-Anson B; Kulisevsky J; Carrió I
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2183-2189. PubMed ID: 27349245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of somatosensory evoked potentials with striatal glucose consumption measured by positron emission tomography in the early diagnosis of Huntington's disease.
    Kuwert T; Noth J; Scholz D; Schwarz M; Lange HW; Töpper R; Herzog H; Aulich A; Feinendegen LE
    Mov Disord; 1993; 8(1):98-106. PubMed ID: 8419813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does reduced [(123)I]-FP-CIT binding in Huntington's disease suggest pre-synaptic dopaminergic involvement?
    Gamez J; Lorenzo-Bosquet C; Cuberas-Borrós G; Carmona F; Hernández-Vara J; Castilló J; Castell-Conesa J
    Clin Neurol Neurosurg; 2010 Dec; 112(10):870-5. PubMed ID: 20724066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human striatal neuroblasts develop and build a striatal-like structure into the brain of Huntington's disease patients after transplantation.
    Gallina P; Paganini M; Lombardini L; Mascalchi M; Porfirio B; Gadda D; Marini M; Pinzani P; Salvianti F; Crescioli C; Bucciantini S; Mechi C; Sarchielli E; Romoli AM; Bertini E; Urbani S; Bartolozzi B; De Cristofaro MT; Piacentini S; Saccardi R; Pupi A; Vannelli GB; Di Lorenzo N
    Exp Neurol; 2010 Mar; 222(1):30-41. PubMed ID: 20026043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thalamic metabolism and symptom onset in preclinical Huntington's disease.
    Feigin A; Tang C; Ma Y; Mattis P; Zgaljardic D; Guttman M; Paulsen JS; Dhawan V; Eidelberg D
    Brain; 2007 Nov; 130(Pt 11):2858-67. PubMed ID: 17893097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.